PSI is a leading full-service CRO operating globally.
98% of PSI-managed clinical trials complete patient enrollment on or ahead of schedule.
PSI's exceptional repeat and referral business rate distinguishes PSI in the market place as a "no-nonsense" CRO that delivers across trials of all sizes and levels of complexity.
PSI has successfully performed Phase II/III studies in the following infectious disease indications:
- Acute bronchitis
- Candidiasis
- Oropharyngeal
- Esophageal
- Invasive
- ENT infections
- Hepatitis
- Herpes simplex
- Herpes zoster
- HIV/AIDS
- HIV-associated infections
| - Influenza
- Intraabdominal infections
- Meningitis
- Otitis media
- Peritonitis and IAI
- PID
- Pneumonia
- Sepsis
- Skin infections
- Tuberculosis
- UTI
- Vaccine augmentation
|
PSI employs physicians as full-time monitors and project managers, most of whom are board certified specialists, including internists, infectious disease specialists, pulmonologists, dermatologists, ENT-specialists, gynecologists, surgeons, and urologists.